Prelude Therapeutics annual debt-to-equity ratio
2021
2022
2023
2024
2025
Prelude Therapeutics Debt-to-Equity Ratio Growth & History (PRLD)
Prelude Therapeutics's debt-to-equity ratio was 0.26 for fiscal 2025.
View full Prelude Therapeutics company overviewPrelude Therapeutics annual debt-to-equity ratio history
| Fiscal year | Period ended | Debt-to-equity ratio | Change | Growth |
|---|---|---|---|---|
| 2025 | 2025-12-31 | 0.26 | 0.12 | +89.02% |
| 2024 | 2024-12-31 | 0.14 | 0.07 | +92.50% |
| 2023 | 2023-12-31 | 0.07 | 0.06 | +659.88% |
| 2022 | 2022-12-31 | 0.01 | 0.00 | +54.02% |
| 2021 | 2021-12-31 | 0.01 | — | — |
Prelude Therapeutics quarterly debt-to-equity ratio
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | Debt-to-equity ratio | Change | YoY change |
|---|---|---|---|---|
| Q2 2026 | 2026-06-30 | 0.13 | −0.10 | −44.14% |
| Q1 2026 | 2026-03-31 | 0.29 | 0.12 | +69.54% |
| Q4 2025 | 2025-12-31 | 0.26 | 0.12 | +89.02% |
| Q3 2025 | 2025-09-30 | 0.31 | 0.19 | +163.09% |
| Q2 2025 | 2025-06-30 | 0.24 | 0.14 | +136.56% |
| Q1 2025 | 2025-03-31 | 0.17 | 0.09 | +107.49% |
| Q4 2024 | 2024-12-31 | 0.14 | 0.07 | +92.50% |
| Q3 2024 | 2024-09-30 | 0.12 | 0.11 | +5715.28% |
| Q2 2024 | 2024-06-30 | 0.10 | 0.10 | +2690.20% |
| Q1 2024 | 2024-03-31 | 0.08 | 0.08 | +955.66% |
| Q4 2023 | 2023-12-31 | 0.07 | 0.06 | +659.88% |
| Q3 2023 | 2023-09-30 | 0.00 | −0.00 | −68.77% |
| Q2 2023 | 2023-06-30 | 0.00 | −0.00 | −52.69% |
| Q1 2023 | 2023-03-31 | 0.01 | −0.00 | −7.69% |
| Q4 2022 | 2022-12-31 | 0.01 | 0.00 | +54.02% |
| Q3 2022 | 2022-09-30 | 0.01 | −0.00 | −7.49% |
| Q2 2022 | 2022-06-30 | 0.01 | 0.00 | +29.98% |
| Q1 2022 | 2022-03-31 | 0.01 | 0.00 | +36.56% |
| Q4 2021 | 2021-12-31 | 0.01 | — | — |
| Q3 2021 | 2021-09-30 | 0.01 | — | — |
| Q2 2021 | 2021-06-30 | 0.01 | — | — |
| Q1 2021 | 2021-03-31 | 0.01 | — | — |
Prelude Therapeutics debt-to-equity ratio trends
Between the periods ended 2021-12-31 and 2025-12-31, Prelude Therapeutics's debt-to-equity ratio increased from 0.01 to 0.26, a change of 0.25. The latest reported quarter, Q2 2026, shows 0.13.
About the metric
What the debt-to-equity ratio means
The debt-to-equity ratio compares interest-bearing debt with shareholders’ equity. It helps show how much debt financing a company uses relative to its accounting equity, but useful comparison levels vary by industry.
Calculation and source
How debt-to-equity is calculated
TickerStat calculates debt-to-equity as total interest-bearing debt divided by SEC-reported shareholders’ equity for the same balance-sheet date. Total liabilities are not treated as debt, and periods with non-positive equity are omitted. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Prelude Therapeutics source filings ↗Community posts
Prelude wins FDA clearance to begin testing a new breast-cancer candidate
Prelude Therapeutics ($PRLD) received FDA clearance of its investigational-new-drug application for PRT13722, an oral KAT6A-selective degrader being developed for hormone-receptor-positive, HER2-negative breast cancer. The company expects t ...